Earlier today, the US Food and Drug Administration (FDA) approved relugolix, (Orgovyx, from Myovant Sciences), the first, oral luteinizing hormone releasing hormone (LHRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, GnRH, LHRH, Myovant, Orgovyx, relugolix | 6 Comments »
The results of the Phase III HERO trial of relugolix — the first oral LHRH antagonist for treatment of advanced prostate cancer — have now been reported in the New England Journal of Medicine (NEJM) and at the “virtual” annual meeting of the American Society for Clinical Oncology (ASCO). … REAR MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: antagonist, antiandrogen, HERO, LHRH, oral, relugolix, trial | 1 Comment »
A poster presentation given the other day at the annual meeting of the Canadian Urological Association addressed the relative cardiovascular risks of LHRH agonist and antagonist therapies. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, cardivascular, complication, LHRH, risk | Leave a comment »
A new paper from a panel of experts in the UK has suggested that the use of LHRH antagonists (e.g., degarelix) may be more appropriate than the use of LHRH agonists (e.g., leuprolide acetate of goserelin acetate) in some prostate cancer patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, cardiovascular, LHRH, risk | 3 Comments »
Today’s news contained items that run the spectrum from the clinical value of tomatoes and lycopene via the cardiovascular side effects of LHRH agonists and antagonists to the question of whether proton beam radiation therapy is really cost-effective. So here are the “news shorts” for the day: … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: agonist, antagonist, cost-effectiveness, LHRH, lycopene, proton beam, PSA density, side effect, testosterone, tomato | 3 Comments »
One of our regular readers has asked us to comment on a paper suggesting the possibility of “significant improvement” in various outcomes for men initially treated with the LHRH antagonist degarelix as compared to the LHRH agonists leuprolide acetate and goserelin acetate. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, benefit, Degarelix, LHRH, outcome, survival | 1 Comment »
At least three new LHRH receptor antagonists — i.e., drugs similar to degarelix (Firmagon) — are in development at the present time: elagolix, relugolix, and ASP-1707. However, unlike degarelix, all three are agents that would act as oral drugs as opposed to drugs one has to be given as long-term injections. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: antagonist, ASP-1707, elagolix, LHRH, oral, relugolix, TAK-385 | Leave a comment »
The full text of a recent review on the use of LHRH receptor agonists (e.g., leuprolide acetate, goserelin acetate) asnd LHRH receptor antagonists (e.g., degarelix) has recently been published by Shore et al. in Prostate Cancer and Prostatic Diseases. The full text of the article is also available on line on the Medscape Oncology web site.
Filed under: Management, Treatment | Tagged: agonist, antagonist, LHRH, receptor, review | 3 Comments »
According to a corporate media release, a company called Spectrum Pharmaceuticals has initiated enrollment of an additional 150 patients into a Phase IIb trial of a new LHRH receptor antagonist called ozarelix (a drug with a similar mechanism of action to degarelix or Firmagon) for the treatment of advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: antagonist, LHRH, ozarelix | 2 Comments »
The question of whether an LHRH antagonist (such as degarelix) is really a better first-line hormone therapy than an LHRH agonist (e.g., leuprolide acetate) is still not fully answered. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, Degarelix, leuprolide, LHRH | Leave a comment »
First-line androgen deprivation therapy (ADT) for a man with metastatic prostate cancer has long been been either surgical or medical castration. In the case of medical castatration, the form of medication most commonly used since the mid to late 1980s has been an LHRH agonist (e.g., leuprolide acetate). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, LHRH, suppression, testosterone | 2 Comments »
When all the drugs in the same class have the same general clinical impact, this is known as a “class effect.” As an example, all statins (hydroxymethylglutaryl–coenzyme A reductase inhibitors) will lower risk for certain types of cardiovascular event because they lower levels of cholesterol. That is a “class effect.” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: agonist, antagonist, GnRH, LHRH | 5 Comments »
We are returning to “normal” today with the standard “news reports.” Today’s items deal with:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: agonist, antagonist, biomarkers, gefitinib, Iressa, LHRH, magnetic resonance imaging, MRI | 2 Comments »
Klotz et al. have now published the complete results of one of the Phase III clinical trials designed to evaluate the effectiveness and the safety of degarelix — a second-generation LHRH antagonist — in the management of hormone-sensitive prostate cancer. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: antagonist, Degarelix, LHRH | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 